Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03742895 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
A Phase 2 study of Advanced Solid Neoplasms, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 326
- Enrollment target
- 20
- Study locations
NCT03742895 is a Phase 2 study of Advanced Solid Neoplasms that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 326 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT03742895, a Phase 2 study of Advanced Solid Neoplasms, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 326 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).
Conditions Studied
Interventions
- DRUG Olaparib
Study Locations (20)
New York
- Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 0126) - Harrison
- VA New York Harbor Healthcare System Manhattan ( Site 0094) - New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0057) - New York
- Memorial Sloan Kettering Cancer Center ( Site 0026) - New York
California
- St Joseph Heritage Healthcare-Oncology ( Site 0056) - Fullerton
- Cedars Sinai Medical Center ( Site 0002) - Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0007) - San Francisco
Georgia
- Winship Cancer Institute of Emory University ( Site 0025) - Atlanta
- Augusta University ( Site 0028) - Augusta
Maryland
- University of Maryland ( Site 0050) - Baltimore
- Weinberg Cancer Institute at Franklin Square ( Site 0054) - Baltimore
Arizona
- The University of Arizona Cancer Center - North Campus ( Site 0011) - Tucson
Colorado
- Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0092) - Aurora
Kentucky
- Markey Cancer Center ( Site 0018) - Lexington
Massachusetts
- University of Massachusetts ( Site 0017) - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2018-12-12 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03742895
The ClinicalTrials.gov registry entry for NCT03742895 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Olaparib is the first listed.
NCT03742895 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT03742895 about?
NCT03742895 is a clinical study titled "Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)". This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair ...
What is the current status of trial NCT03742895?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 326 participants. The study started on 2018-12-12. Estimated completion is 2026-06-30.
What conditions does trial NCT03742895 study?
This clinical trial studies the following conditions: Advanced Solid Neoplasms.
What interventions are being tested in trial NCT03742895?
The interventions under investigation include: Olaparib (DRUG).
Who is sponsoring clinical trial NCT03742895?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03742895 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.